Introduction
The prevalence of the BCR-ABL-negative chronic myeloproliferative neoplasm (MPN), polycythemia vera (PV), essential thrombocytosis (ET) and myelofibrosis (MF) in the United States has been estimated at 80-100 000 cases, with an incidence rate of approximately 2-5 cases per 100 000 persons per year. Although the majority of patients with PV are positive for the JAK2V617F tyrosine kinase mutation, approximately 50% of patients with ET and MF are negative for it. [1] [2] [3] We previously identified and reported a point mutation in the thrombopoietin receptor (MPLW515L) that is present in approximately 10% of patients with JAK2V617F-negative MF. 4 Analogous to the JAK2V617F mutation, MPLW515L constitutively activates the downstream tyrosine kinases, STAT3 and STAT5, transforms hematopoietic cells to cytokine-independent growth and produces features of ET with accompanying marrow fibrosis, in an in-vivo murine retroviral bone marrow transplant (BMT) model. In contrast, the expression of JAK2V617F in a murine BMT assay results in a MPN most similar to PV, with marked erythrocytosis but no significant thrombocytosis. [4] [5] [6] [7] [8] Therefore, we decided to utilize the MPLW515L murine BMT assay to test whether the thrombocytosis and fibrosis can be treated with a smallmolecule JAK2 inhibitor, similar to the reduction of erythrocytosis in the JAK2V617F model. 9 Here, we report the efficacy of a small-molecule JAK2 inhibitor, EXEL-8232, with suitable characteristics for in vivo use in humans, in a murine model of thrombocytosis. Furthermore, we utilize this model to develop and validate surrogate end points for response in treated animals, similar to what we have shown previously for JAK2V617F-positive MPNs. 9 These surrogates include assessment of abrogation of erythropoietin-independent colony formation, which is considered a hallmark of the MPNs, and inactivation of specific downstream effectors, such as phospho-STAT5, phospho-STAT3 and phospho-ERK. In our present study, we also observed that the inhibitor has minimal impact on other lineages, at the dosages that reverse thrombocytosis. EXEL-8232 is well tolerated and an effective therapeutic agent in murine BMT model of MPLW515L MPN, and therefore may also be a suitable therapy for other JAK2V617F-negative MPN, such as those carrying Exon 12 mutations, and also for JAK2V617F-positive MPN with thrombocytosis.
Materials and methods

Reagents
The exelixis-8232 compound was synthesized by Exelixis (San Francisco, CA, USA). Stock solutions were made in dimethylsulfoxide, and subsequently diluted in RPMI-1640 medium for use. Anti-phospho-STAT5 (Tyr694) (polyclonal), anti-STAT5 (polyclonal), anti-phospho-STAT3, anti-STAT3, anti-phospho-S6 and anti-S6 were purchased from Cell Signaling (Beverly, MA, USA).
Expression vectors and cell culture
The MSCV-MPL-IRES EGFP retroviral vector was generated as previously described. 4 293T cells were grown in Dulbecco's modied Eagle's medium with 10% fetal bovine serum. Transient co-transfection of 293T cells and generation of retroviral supernatant were performed using Fugene (Roche, Nutley, NJ, USA) according to manufacturer's guidelines, and murine bone marrow cells were transduced with viral supernatant. HEL92.1.7, CFPAC-1, SET-2 and UKE-1 cells were grown in RPMI medium 1640 or Dulbecco's modied Eagle's medium containing 10% fetal bovine serum.
Cell proliferation and phosphorylation inhibitor assay
For phosphoinhibition assays, cells were exposed to 30, 100 and 300 mg/kg of the compound, and individual inhibitory concentrations (IC 50 s) and effective dosages (ED 50 s) calculated and also the percent of phosphoinhibition was assessed by western blot.
Transfection of primary cells
The MPLW515L mutation was introduced by site-directed mutagenesis (QuikChange kit; Stratagene, La Jolla, CA, USA) into a plasmid that carries the full-length human MPL cDNA (Invitrogen, Carlsbad, CA, USA). Once confirmed by DNA sequencing, the MPLW515L cDNA was subcloned into a retroviral vector (Stratagene). Recombinant retroviral particles were produced in HEK293 cells and subsequently transduced into primary murine bone marrow cells.
Cell-free kinase activity assays (IC 50 determinations)
IC 50 values for EXEL-8232 were determined commercially for the screening of all Janus kinase family members, including JAK1, JAK3 and Tyk2 as well as 56 other tyrosine kinases and serine threonine kinases. ATP concentration was set to approximately the Km value for each kinase.
Western blot analysis
Cells were treated with dimethylsulfoxide and increasing concentrations of inhibitor for 4 h in RPMI-1640 medium before collection in 1 Â Cell Lysis Buffer (Cell Signaling), containing 1 mM polymethylsulfonyl fluoride and protease-inhibitor cocktail tablets (Roche). Protein lysates were quantified using Bradford assay. Similar protein amounts were mixed with sample buffer (Invitrogen) and boiled for 5 min, and separated on a 4-15% Tris-HCl gradient electrophoresis gel (Invitrogen). Gels were blotted onto a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA), which was blocked in 5% nonfat dry milk, and incubated with primary antibodies in either blocking solution or 5% Bovine serum albumin. The membranes were subsequently incubated with a mixture of anti-rabbit/mouse Ig and phosphorylation signal was quantified.
Murine models and analysis of mice after treatment with EXEL-8232 Murine HEL92.1.7 xenograft tumor model had been established by bilateral subcutaneous injection of 1 Â 10 6 Hel 92.1.7 cells in the back of each mouse, and tumor growth assessed and treatment initiated by oral gavage.
The murine BM transplant model was generated and analyzed exactly as previously described. 4, 5 Briefly, C57BL/6 mice (Taconic, Germantown, NY, USA) were intravenously injected with 1 Â 10 6 whole bone marrow expressing MPLW515L. Following 12 days after BMT, EXEL-8232 was administered by oral gavage twice daily (b.i.d.) at 30, 100 mg/kg or placebo for 28 days. Differential blood counts were assessed by retro-orbital non-lethal eyebleeds using ethylenediaminetetraacetic acid glass capillary tubes before study initiation, on a weekly basis during the study and at study endpoint. MPLW515L BMT C57/ Bl6 mice were killed at study endpoint or at times indicated based on an IUCAC-approved protocol that includes assessment of morbidity by 410% loss of weight, scruffy appearance, lethargy and/or splenomegaly extending across the midline. For histopathology, tissues were fixed in 10% neutral-buffered formalin, embedded in paraffin and stained with hematoxylin and eosin or to assess for fibrosis stained with reticulin. Images of histological slides were obtained on a Nikon Eclipse E400 microscope (Nikon, Tokyo, Japan) equipped with a SPOT RT color digital camera model 2.1.1 (Diagnostic Instruments, Sterling Heights, MI, USA). Images were analyzed in Adobe Photoshop 6.0 (Adobe Systems, San Jose, CA, USA). For flow cytometry, cells were washed in phosphate-buffered saline, 2% fetal bovine serum, blocked with Fc-Block (BD Pharmingen, San Diego, CA, USA) for 10 min on ice, and stained with monoclonal antibodies in phosphate-buffered saline, 2% FCS for 30 min on ice. Antibodies used were: allophycocyaninconjugated ter119, Gr-1, CD4 and B220; and phycoerythrinconjugated Mac1, CD8 (all 1:200) and CD71 (1:100) rat antimouse (BD Pharmingen). After washing, the cells were resuspended in phosphate-buffered saline, 2% FCS containing 0.5 mg/ml 7-amino-actinomycin D (BD Pharmingen) to allow distinguishing of nonviable cells. Flow cytometry was performed on a FACS Calibur cytometer (BD Biosciences, San Jose, CA, USA), at least 10 000 events were acquired and data were analyzed using FloJo software (FloJo, Ashland, OR, USA). The results are presented as graphs and representative dot-plots of viable cells selected on the basis of scatter and 7-aminoactinomycin D staining.
Colony assays
To assess colony-forming capacity during in vivo drug treatment, 1 Â 10 5 BM and spleen cells or peripheral blood from MPLW515L mice treated with 30 or 100 mg/kg of drug or placebo were harvested at study endpoint, plated in duplicate in methylcellulose (M3234: Stem Cell Technologies, Vancouver, BC, Canada) according to the manufacturer's protocol and counted after 7 days in culture. For colony assays with human MPN patient samples, whole bone marrow and peripheral blood of MF and ET patients, 1 Â 10 5 cells/ml of peripheral blood were plated in methylcellulose (H4534 Stem Cell Technologies). For colony assays performed for in vitro drug efficacy studies, serum was collected from animals 3 h post dosing with 30, 100 mg/kg or placebo, and primary cells were co-cultured with mouse serum.
Flow cytometric staining of intracellular phosphorylated STAT5, STAT3 and S6
Freshly isolated BM from MPLW515L-transplanted animals was harvested 3 h after dosing with 100 mg/kg EXEL-8232. As a control, placebo-treated MPLW515L bone marrow was used, fixed immediately with 2% paraformaldehyde (Polysciences Inc., Warrington, PA, USA) and permeabilized with 90% icecold methanol or cultured for 4 h in RPMI þ 1% bovine serum albumin at 37 1C, stimulated with IL-3, SCF and IL-6 (Stem Cell Technologies) or EPO (Cell Sciences, Canton, MA, USA). Staining was performed as previously described. 10 Briefly, cells were incubated with anti-phospho-STAT5 phycoerythin (BD pharmingen) 1:50, anti-phospho-STAT3 1:100 (Cell signaling) and antiphospho-S6 1:100 (Cell signaling, Canton, MA, USA), respectively. Following a final wash, the samples were sorted by flow cytometry on a FACS Aria and analyzed using FloJo software.
Statistical analysis, animal studies and patient sample collection
Pooled data are displayed as mean±s.d. To assess statistical significance among the two groups, the paired Student's t-test EXEL-8232 treats murine model of myeloproliferative neoplasm G Wernig et al was used. Animal studies were conducted using an IUCACapproved animal protocol at our institution. In addition, studies involving human material were obtained under the auspices of informed consent and the appropriate Institutional Review Board approved the study.
Results
Characteristics and pharmacokinetic properties of EXEL-8232
EXEL-8232 is an experimental, potent small-molecule inhibitor of JAK2 with an IC 50 of only 2 nM. EXEL-8232 is selective for JAK2, with an IC 50 490 nM for 56 other tyrosine and serinethreonine kinases. In addition, within the family of Janus kinases, the compound is selective for JAK2 with substantially higher IC 50 values for JAK1, JAK3 and TYK2 (Table 1) . EXEL-8232 abolished constitutive phosphorylation of STAT1, STAT3 and STAT5, and reduced proliferation in three different cell lines (Table 1) . We tested EXEL-8232 in a HEL92.1.7 xenograft-tumor model, in which HEL cells were injected subcutaneously into immunocompromised mice and treated with 30, 100 or 300 mg/kg of the drug and the percentage of inhibition of phosphorylation of STAT1, STAT3 and STAT5 quantified. At 30 mg/kg, only partial inhibition of STAT1 and STAT3, and no inhibition of STAT5 was achieved, whereas at 100 mg/kg B80% inhibition was achieved, that was only slightly further enhanced at the 300 mg/kg dose (Figures 1a and b) .
As a next step, the ED to achieve 90% and/or 50% inhibition of phosphorylation of STAT1, STAT3 and STAT5 were determined (Figures 1c and d) . To assess whether EXEL-8232 had an effect in MPL-mutant primary cells, we transduced murine bone marrow with MPLW515L-EGFP-expressing retrovirus, sorted for green fluorescent protein (GFP) expression and performed colony assays of MPLW515L-transformed peripheral blood, bone marrow and splenic cells under culture conditions where either 0.5 or 3.0 mM of the EXEL-8232 compound was added. Overall colony growth was reduced at the low concentration and abrogated at culture conditions with the high concentration of EXEL-8232 compound. This observation was even more pronounced in the absence of erythropoietin (Supplementary Figure 1) .
Efficacy of EXEL-8232 in a murine BMT model of MPLW515L-induced ET, a JAK2V617F-negative MPN Study design. We tested the potential of EXEL-8232 in the MPLW515L BMT mouse model as previously described. 4 Briefly, murine bone marrow cells were harvested and infected with a MSCV retrovirus expressing the mutant MPLW515L cDNA and GFP. Because of the rapidly fatal course of disease in this model, we initiated treatment on day 12 after BMT, the earliest time point at which disease was established. Fully established disease was determined by peripheral blood chimerism that was determined by GFP expression greater than 80%, thrombocytosis and leukocytosis (Table 2 ). Fifteen animals were randomly assigned to treatment or vehicle groups (n ¼ 15 mice/group), EXEL-8232 compound was administered for 28 days every 12 h (q12 h) by oral gavage at doses of 30 mg/kg or 100 mg/kg or placebo, respectively, and the trial was repeated twice. In addition, to determine non-specific and toxic effects, we treated wild-type animals (n ¼ 4 for each group).
Response of treated animals. Animals treated with 100 mg/kg reduced high platelet counts in excess of 2 million/ml (Po0.001 for 100 mg/kg and Po0.05 for 30 mg/kg group) and normalized leukocytosis from a median of 134 000/ml (Po0.01 for 100 mg/kg) compared with vehicle-treated controls (Table 2) . Furthermore, drug treatment eliminated extramedullary hematopoiesis in the spleen and liver as well as bone marrow fibrosis (Figures 2A  and B) . Of note, EXEL-8232 had no impact on red blood cell formation in diseased animals or in wild-type controls, and wild-type animals treated with either dosage of 30 mg/kg or 100 mg/kg did not develop thrombocytopenia (Table 2, Figure 2b ). There was no statistically significant difference in survival amongst all three treatment arms in the study where animals were treated prospectively and no death incidences occured (Supplementary Figure 2a) . In animals that were treated retrospectively (day 16 post BMT), high mortality (B50%) was observed within the first week. However, from day 8 until study endpoint, animals in the 100 mg/kg arm showed slightly improved survival (1 death incidence) compared with placebo and 30 mg/kg arm (Supplementary Figure 2b) , which was not statistically significant. Animals in the 100 mg/kg arm showed significantly increased body weights and significantly decreased peripheral blood GFP levels at study endpoint compared with the placebo arm ( Supplementary Figures 3 and 4) .
Efficacy of EXEL-8232 as assessed by flow cytometry and hematopoietic colony formation
At study endpoint after 28 days of treatment, flow cytometric analysis was performed on peripheral blood, bone marrow and splenocytes of mice treated with EXEL-8232 or placebo. Most remarkably, we noticed a statistically significant decrease in MPL-mutant early erythroid precursors in the bone marrow and complete elimination in the peripheral blood. In addition, there was a reduction of mature neutrophils in the bone marrow and spleen in mice treated with 100 mg/kg EXEL-8232 (Figure 3a) .
The potential effect of the drug on lymphopoiesis was difficult to assess in the context of a fulminant MPN after lethal irradiation for BMT. Thus, to better understand the effects of 
EXEL-8232 on normal hematopoietic elements, a cohort of three groups of wild-type nonirradiated animals (n ¼ 4) were treated concurrently for 28 days by oral gavage with vehicle, 30 mg/kg or 100 mg/kg of drug bid, respectively. Differential blood counts were normal apart from a slight reduction in total lymphocyte count (Po0.05). Of particular note, none of the animals became anemic (Table 2) . When compared with placebo, platelet counts were higher in the high-treatment group, demonstrating the spectrum of normal variability and suggesting that the manner of inhibition of platelet production is highly specific. We detected no effect on T-cell number in either the bone marrow or spleen of animals treated with EXEL-8232 by flow cytometric analysis. However, we observed a statistically significant reduction, albeit modest, in B-cell number in the bone marrow of MPLW515L and the bone marrow of wild-type animals (Po0.05), but not in other compartments. Thus, 28 days of treatment with EXEL-8232 had no appreciable effect on T-cell number, consistent with lack of inhibition of JAK3 observed in vitro. In addition, there was no reduction in cells of the neutrophilic/monocytic lineage that express both Gr1 and Mac1 markers. This observation indicates that the drug has less inhibitory activity for wild-type hematopoietic cells than in MPLW515L-positive cells (Figure 3b ). Colony assays performed on splenocytes at study endpoint showed an overall decrease in colony formation due to decreased erythroid and myeloid colony-forming capacity. Abbreviations: HCT, hematocrit; WBC, white blood cells.
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There were similar but less pronounced findings in the bone marrow. In the peripheral blood, total colony formation was abrogated in the high-dose treatment arm (Figure 3c and data not shown).
Assessment of surrogate end points for response
We used traditional murine clinical response criteria such as differential blood counts, histopathology including reticulin stains for MF assessment, immunophenotypic characterization and colony-forming capacity. We then correlated these conventional response criteria to functional read-outs for disease, and established surrogate assays to measure for loss of endogenous erythroid colony growth in human MPN samples. We also assessed inhibition of the involved downstream signaling pathways in vitro and in vivo by loss or reduction of phosphorylation of STAT5, STAT3 and S6K1. MPN are associated with the pathognomonic finding of erythropoietin-independent erythroid colony formation, offering an opportunity to assess functional eradication of this population by JAK2 inhibitors. We observed that erythropoietinindependent erythroid colony formation of JAK2V617F-negative ET and MF peripheral blood was reduced or abrogated after treatment with 0.5 or 3.0 mM compound (Figure 4a) . We also noticed a dose-dependent inhibition of erythroid colony formation of MF patient peripheral blood in response to treatment with mouse serum collected 3 h after treatment with both dose levels of inhibitor. This effect was even more pronounced under Epo-free culture conditions, resulting in a complete loss of erythroid colonies in cultures treated with serum from mice dosed with both drug regimens (Figure 4b and data not shown).
We next assessed the potential value of measuring activation status of signal transduction targets of MPLW515L, including STAT5, STAT3 and S6K1, in response to therapy. We first characterized the effect of EXEL-8232 on signal transduction pathways activated by MPLW515L in vivo using flow cytometry with phosphospecific antibodies to STAT5, STAT3 or S6K1, an effector of the PI3K/AKT pathway. Flow cytometry was used to isolate disease-relevant hematopoietic progenitors derived from animals by gating on GFP þ CD71 þ or CD71 þ ter119 þ erythroid precursors, CD41 þ megakaryocytic precursors or GFP þ Mac1 þ Gr1 þ myeloid cells that harbored the MPLW515L allele. We assessed the activation state of signaling intermediates in cells starved of growth factors for 4 h and then stimulated with interleukin 3 (IL3) and thrombopoietin. MPLW515L-expressing cells had activated basal signaling levels, but upon cytokine stimulation the degree of phosphorylation (Figure 4c ). Next, we tested whether flow cytometry could be used to measure specific response to therapy in treated animals in vivo under steady-state conditions. Cells were harvested from animals at study endpoint, 3 h after the last dosage with EXEL-8232, immediately stained and gated by flow cytometry for the markers described above without prior cytokine stimulation for phosphoSTAT5 or phosphoSTAT3 and phosphoS6 in GFP-and CD71-positive immature erythroid precursors, GFP-and CD41-positive megakaryocytes as well as GFP-and Gr1/Mac1-positive myelomonocytic cells harvested from EXEL-8232-treated vs placebo-treated mice. The data indicate that EXEL-8232 is capable of inhibiting phosphorylation of pSTAT5, pSTAT3 and pS6 downstream effectors of the MPL-JAK-STAT signaling pathway in erythroid, myeloid and megakaryocytic primary hematopoietic cells expressing MPLW515L, derived from animals after in vivo treatment under steady-state conditions (Figure 4d ).
Discussion
In this study, we show that EXEL-8232 is selective for JAK2 in vitro and is of therapeutic benefit in a murine model of ET in vivo. Strikingly, the oral treatment of a BMT model of disease induced by MPLW515L normalized platelet counts in excess of 2 million/ml, leukocytosis and extramedullary hematopoiesis in the spleen as well as bone marrow fibrosis. Importantly, EXEL-8232 has minimal hematopoietic toxicity, in that wild-type animals treated with the compound did not develop thrombocytopenia nor anemia or leukocytopenia. In addition, we were able to establish surrogate end points for response to treatment, such as reduction of endogenous erythroid colonies and inhibition of activated P-STAT5, P-STAT3 and P-S6K1 in erythroid and myeloid precursors. A recent study utilizing the same retroviral model but in another mouse strain (Balb/c) and a different inhibitor, showed data which are overall comparable to our study. We chose the C57Bl6 strain that results in a milder disease phenotype. In particular, the leukocytosis is less pronounced but platelet numbers are similarly elevated, thus making it a more relevant model for ET. It thus allowed us to assess more accurately the JAK2 inhibition on thromobocytosis. In vitro data of both studies show sufficient sensitivity and specificity of two different smallmolecule JAK2 inhibitors, pathway specificity in vitro and in vivo, as well as response to treatment, such as improved platelet counts, WBC, body weights, decreased splenic weights; however both studies were not able to show elimination of the malignant clone.
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A significant proportion (B50%) of ET and MF patients lack the JAK2V617F mutation. 1, 2, [12] [13] [14] The MPLW515L and JAK2 Exon 12 alleles account for an additional B10% and B2%, respectively, of the JAK2V617F-negative patients 4, 14 and less commonly TET2, ASXL1, CBL, IDH and IKZF1. 15 There are thus two key points to ensue from the observations in this report.
First, these data indicated that even though patients with the MPLW515L mutation are wild type for JAK2, cells transformed by this allele retain dependence on JAK2 and sensitivity to pharmacological inhibition of JAK2. Thus, agents such as EXEL-8232 may be of value to patients with MPLW515L mutations and also to MPN patients with the JAK2V617F mutation, and this notion has been supported by the outcomes of recent clinical trials. [16] [17] [18] [19] [20] Second, we do not yet know the identity of all the mutations that are responsible for the remaining cases of MPN, but there is evidence that the JAK-STAT pathway is also activated in these patients. These observations suggest the hypothesis that even in the absence of known causal mutations, patients with MPN may yet benefit from pharmacological inhibition of JAK2, as is observed in the MPLW515L mutation as a known upstream activator of JAK2.
In addition, most previous studies with the JAK2V617F animal model did not address the potential of JAK2 inhibitors for treating thrombocythemia associated with these MPN, in that thrombocytosis is not observed in the JAK2V617F murine model. 5, 9 In contrast, robust thrombocytosis is induced in the MPLW515L murine BMT model. 4, 11 We therefore used this system to evaluate platelet response to the JAK2-specific smallmolecule inhibitor EXEL-8232. We designed these studies by treating animals for 28 days with EXEL-8232 from day 10 post BMT and demonstrated dose-dependent responses to therapy as well as insights into potential side effects. We observed that the drug was well-tolerated, with statistically significant normalization in platelet counts and WBC, marked attenuation or elimination of reticulin fibrosis, flow cytometric evidence for reduction in GFP-expressing myeloid progenitors and reduction of colony formation of these populations in vitro. Our data suggest the prospect that, JAK2-specific inhibitors could be used to treat thrombocytosis and MF in JAK2V617F-negative MPN patients. Our data also indicate that, at least in short-term assays there is minimal toxicity in the hematopoietic system, including T cells, an important safety characteristic for a compound used in the treatment of this relatively indolent blood cancer.
Finally, molecular assays to predict initial response to therapy and ongoing monitoring of response may be of value in design and implementation of clinical trial design. Our data indicate that, erythropoietin-independent erythroid colony can be utilized in MPN patients 21 for functional assessment of response to JAK2 inhibition, for example, response to therapy of the malignant clones for each individual patient. In addition, assessment of the activation state of STAT5, STAT3 and S6 K, effectors of activated thrombopoietin receptor or JAK2 may be utilized as pharmacodynamic marker of response. These types EXEL-8232 treats murine model of myeloproliferative neoplasm G Wernig et al of surrogate end points for response may thus enable more rapid assessment of the clinical potential of JAK2 inhibitors. In summary, EXEL-8232, a selective JAK2 inhibitor, may be useful for the treatment of thrombocytosis, MF and splenomegaly associated with MPLW515L-mutated MPN, and may have activity in other MPN in which JAK2 is not mutated.
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